Oliceridine, also known as TRV130, is a µ- opioid receptor agonist, that is currently under evaluation in human clinical trials for the treatment of acute severe pain. It is a functionally selective μ-opioid receptor agonist developed by Trevena Inc. TRV130 elicits robust G protein signaling, with potency and efficacy similar to morphine, but with far less β-arrestin 2 recruitment and receptor internalization, it displays less adverse effects than morphine.

 

Brand: BCM

 

Isomeric SMILES: COC1=C(SC=C1)CNCC[C@]2(CCOC3(C2)CCCC3)C4=CC=CC=N4.C(=C/C(=O)O)\C(=O)O  

 

InChIKey: LJQUAERICCVBQQ-CMABEYDLSA-N  

 

InChI: InChI=1S/C22H30N2O2S.C4H4O4/c1-25-18-7-15-27-19(18)16-23-13-10-21(20-6-2-5-12-24-20)11-14-26-22(17-21)8-3-4-9-22;5-3(6)1-2-4(7)8/h2,5-7,12,15,23H,3-4,8-11,13-14,16-17H2,1H3;1-2H,(H,5,6)(H,7,8)/b;2-1+/t21-;/m1./s1

 

Attribute
[Molecular]	502.63
[Formula]	C22H30N2O2S.C4H4O4
[CAS No.]	1467617-09-9
[Chem Name]	TRV-130 fumarate
[Synonym]	TRV130 (2E)​-​2-​butenedioate (1:1);Oliceridine fumarate;Olinvo fumarate;
[Form]	Solid Powder
[Storage]	Sealed in dry. Stored at -20°C。

Goods Tag